Language
Grade: Pharmaceutical Grade
Factory Location: Xiamen, Fujian
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East
Sample Provided: yes
Payment Terms: L/L
|
Product Information |
|
Product name |
THYMOPENTIN |
|
Molecular Formula |
C30H49N9O9 |
|
Molecular Weight |
268.93 |
|
CAS No. |
69558-55-0 |
|
Quality Standard |
99% up, medical grade |
|
Appearance |
White powder |
|
Sequence |
Arg-Lys-Asp-Val-Tyr-NH2 |
|
Character |
Composed of arginine, lysine, aspartic acid, tyrosine and valine amino acid |
|
COA of Thymopentin |
|
Test Item |
Specification |
Results |
|
Appearance |
White to off-white powder |
Off-white powder |
|
Solubility |
Very soluble in water, slightly soluble in ethanol, insoluble in ethyl acetate, ether and petroleum ether |
Conform |
|
Specific rotation |
-14.0o ~ -22.0o |
-16.5o |
|
Biuret reaction |
Should appear positive reaction |
Positive reaction |
|
IR |
Infrared spectrogram should conform to reference substance |
Conform |
|
HPLC |
Retention time of main peak of test sample should be consistent with reference substance |
Conform |
|
pH |
7.0-9.0 |
8.1 |
|
Water |
NMT 5.0% |
2.6% |
|
Amino acids |
Arg 0.8-1.2 Asp 0.8-1.2 Lys 0.8-1.2 Tyr 0.8-1.2 Val 0.8-1.2 |
Conform |
|
Related substance |
Single impurity NMT 1.5% Total impurity NMT 2.5% |
0.2% 0.3% |
|
Bacterial endotoxin |
< 5EU/mg |
Conform |
|
Assay |
97.0% - 103.0% |
101.1% |
|
Conclusion |
It conforms to the enterprise standard |
|
|
Usage |
Introduction of Thymopentin 69558-55-0:
Pharmacological effects:
Cell immunoregulatory drugs, can induce T cell differentiation and promote the development of T lymphocyte subsets, mature and activation function, and to adjust the proportion of lymphocyte subsets, it close to normal.
Indications:
Can be used to improve the radiotherapy and chemotherapy for cancer patients immunocompromised result. It can normalize and prevent all kinds of cellular immune deficiency to some extent and thus a potential immune modulating agents.
